



A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

# Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®  
non-Medicare members

Revised April 1, 2026

This document lists the medical benefit drugs that have authorization requirements for Blue Cross and Blue Shield Federal Employee Program non-Medicare members.

For dates of service on or after Dec. 1, 2020, providers will have to request authorization from Blue Cross Blue Shield of Michigan for some drugs covered under the medical benefit for Blue Cross and Blue Shield FEP non-Medicare members. Authorization will be required only when members receive the drugs in Michigan.

FEP Medication Authorization Request Forms can be accessed [here](#)

HCPCS code	Brand name	Generic name	Prior authorization
Q2055	Abecma	idecabtagene vicleucel	2/1/2026
J9042	Adcetris	brentuximab vedotin	2/1/2026
J9029	Adstiladrin	nadofaragene firadenovec-vncg	2/1/2026
Q5150	Ahzantive	aflibercept-mrbb	2/1/2026
J1552	Alyglo	immune globulin intravenous	6/1/2024
Q5126	Alymsys	Bevacizumab-maly	4/1/2024
J9999	Amtagvi	lifileucel	2/1/2026
J0225	Amvuttra	vutrisiran	3/1/2024
J0881	Aranesp	darbepoetin alfa	2/1/2026
J1554	Asceniv®	immune globulin, human- slra	12/1/2020
Q2058	Aucatzyl	obecabtagene autoleucel	2/1/2026
J9035, C9257	Avastin	Bevacizumab	4/1/2024
Q5121	Avsola®	infliximab-axxq	1/1/2023
J3490	Avzivi	bevacizumab-tjnj	2/1/2026
J0179	Beovu®	brolocizumab-dblj	12/1/2020
J1414	Beqvez	fidanacogene elaparvovec-dzkt	1/1/2025
J3590	Bildyos	denosumab-nxxp	2/1/2026
J9999	Bilprevda	denosumab-nxxp	2/1/2026
J1556	Bivigam®	immune globulin	12/1/2020



A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

# Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®  
non-Medicare members

Revised April 1, 2026

HCPCS code	Brand name	Generic name	Prior authorization
Q5152	Bkemv	Eculizumab-aeeb	2/1/2026
Q5158	Bomyntra	denosumab-bnht	2/1/2026
Q2054	Breyanzi	lisocabtagene maraleucel	2/1/2026
J2329	Briumvi	ublituximab-xiyy	2/1/2026
Q5124	Byooviz	ranibizumab-nuna	3/1/2024
Q2056	Carvykti	ciltacabtagene autoleucel	2/1/2026
J3392	Casgevvy	exagamglogene autotemcel	2/1/2026
Q5128	Cimerli	ranibizumab-eqrn	3/1/2024
Q5158	Conexxence	denosumab-bnht	2/1/2026
J1551	Cutaquig®	immune globulin	12/1/2020
J1555	Cuvitru®	immune globulin	12/1/2020
J9144	Darzalex Faspro	daratumumabhyaluronidase-fihj	2/1/2026
J7318	Durolane	Hyaluronic Acid Derivatives	2/1/2026
J1413	Elevidys	delandistrogene moxeparvovec-rokl	2/1/2026
J3403	Encelto	fidanacogene elaparvovec-dzkt	2/1/2026
J9358	Enhertu	fam-trastuzumab deruxtecan-nxki	2/1/2026
Q5149	Enzeevu	aflibercept-abzv	2/1/2026
J0885	Epogen	Epoetin Alfa	3/1/2024
Q5151	Epysqli	Eculizumab-aagh	2/1/2026
J7323	Euflexxa	Hyaluronic Acid Derivatives	2/1/2026
J0178	Eylea®	aflibercept	12/1/2020
J0177	Eylea HD	aflibercept	3/1/2024
J1572	Flebogamma® DIF	immune globulin	12/1/2020
Q5108	Fulphila	Pegfilgrastim-jmdb	4/1/2024



A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

# Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®  
non-Medicare members

Revised April 1, 2026

HCPCS code	Brand name	Generic name	Prior authorization
Q5130	Fynetra	Pegfilgrastim-pbbk	4/1/2024
J1560	GamaSTAN	Immune Globulin	2/1/2026
J1569	Gammagard®	immune globulin	12/1/2020
J1566	Gammagard®S/D Less IgA	immune globulin	12/1/2020
J1561	Gammaked®	immune globulin	12/1/2020
J1557	Gammaplex®	immune globulin	12/1/2020
J1561	Gamunex-C®	immune globulin	12/1/2020
J7326	Gel-ONE	Hyaluronic Acid Derivatives	2/1/2026
J7328	GelSyn-3	Hyaluronic Acid Derivatives	2/1/2026
J7320	GenVisc 850	Hyaluronic Acid Derivatives	2/1/2026
J0223	Givlaari	givosiran	3/1/2024
J1447	Granix	tbo-Filgrastim	4/1/2024
J1411	Hemgenix	etranacogene dezaparvovec-drlb	2/1/2026
J9355	Herceptin	Trastuzumab	4/1/2024
J9356	Herceptin Hylecta	Trastuzumab and hyaluronidase-oysk	4/1/2024
Q5146	Hercessi	trastuzumab-strf	2/1/2026
Q5113	Herzuma	Trastuzumab-pkrb	4/1/2024
J1559	Hizentra®	immune globulin	12/1/2020
J7321	Hyalgan	Hyaluronic Acid Derivatives	2/1/2026
J1575	Hyqvia®	immune globulin	12/1/2020
J7322	Hymovis	Hyaluronic Acid Derivatives	2/1/2026
J9256	Imaavy	nipocalimab-aahu	2/1/2026
J9325	Imlygic	talimogene laherparepvec	2/1/2026
Q5098	Imuldosa	ustekinumab-srtf	2/1/2026



A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

# Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®  
non-Medicare members

Revised April 1, 2026

HCPCS code	Brand name	Generic name	Prior authorization
Q5103	Inflixtra®	infliximab-dyyb	12/1/2020
J1745	Infliximab	infliximab	3/1/2024
Q5160	Jobevne	bevacizumab-nwgd	2/1/2026
Q5136	Jubbonti	denosumab-bbdz	2/1/2026
J9354	Kadcyla	ado-trastuzumab emtansine	2/1/2026
Q5117	Kanjinti	Trastuzumab-anns	4/1/2024
J3590	Kebilidi	eladocagene exuparvovec-tneq	2/1/2026
J9271	Keytruda	pembrolizumab	2/1/2026
Q2042	Kymriah®	tisagenlecleucel	12/1/2020
J3590	Lantidra	donislecel-jujn	2/1/2026
J3391	Lenmeldy	atidarsagene autotemcel	2/1/2026
J2778	Lucentis®	ranibizumab	12/1/2020
J3398	Luxturna®	voretigene neparvovec-rzyl	12/1/2020
J3394	Lyfgenia	lovo-cel	2/1/2026
J7327	Monovisc	Hyaluronic Acid Derivatives	2/1/2026
Q5107	Mvasi	bevacizumab-awwb	4/1/2024
J2506	Neulasta	Pegfilgrastim	4/1/2024
J2506	Neulasta Onpro	Pegfilgrastim	4/1/2024
J1442	Neupogen	Filgrastim	4/1/2024
Q5110	Nivestym	Filgrastim-aafi	4/1/2024
Q5148	Nypozi	filgrastim-txid	2/1/2026
Q5122	Nyvepria	Pegfilgrastim-apgf	4/1/2024
J2350	Ocrevus®	ocrelizumab	12/1/2020
J1568	Octagam®	immune globulin	12/1/2020
Q5114	Ogivri	Trastuzumab-dkst	4/1/2024
J3590	Omisirge	omidubicel-onlv	2/1/2026



A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

# Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®  
non-Medicare members

Revised April 1, 2026

HCPCS code	Brand name	Generic name	Prior authorization
J0222	Onpattro®	patisiran	12/1/2020
Q5112	Ontruzant	Trastuzumab-dttb	4/1/2024
J9299	Opdivo	nivolumab	2/1/2026
Q5153	Opuviz	aflibercept-yszy	2/1/2026
J7324	Orthovisc	Hyaluronic Acid Derivatives	2/1/2026
Q5157	Osenvelt	denosumab-bmwo	2/1/2026
Q5159	Ospomyv	denosumab-dssb	2/1/2026
Q9999	Otulfi	ustekinumab-aaaz	2/1/2026
J0224	Oxlumo	lumarisan	3/1/2024
J1576	Panzyga®	immune globulin, human - ifas	12/1/2020
Q5147	Pavblu	aflibercept-ayyh	2/1/2026
J9306	Perjeta	pertuzumab	2/1/2026
J1459	Privigen®	immune globulin	12/1/2020
J0885	Procrit	epoetin alfa	3/1/2024
J0897	Prolia®	denosumab	12/1/2020
Q2043	Provenge	sipuleucel-t/lactated ringers	2/1/2026
Q9996	Pyzchiva	ustekinumab-ttwe	2/1/2026
Q5125	Releuko	Filgrastim-ayow	4/1/2024
J1745	Remicade®	infliximab	12/1/2020
Q5104	Renflexis®	infliximab-abda	12/1/2020
Q5106	Retacrit	Epoetin Alfa-Epbx	3/1/2024
J3590	Rethymic	allogeneic processed thymus tissue-agdc	2/1/2026
Q5123	Riabni	rituximab-arrx	3/1/2024
J9312	Rituxan	rituximab	3/1/2024
J9311	Rituxan Hycela	Rituximab -hyaluronidase human	4/1/2024



A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

# Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®  
non-Medicare members

Revised April 1, 2026

HCPCS code	Brand name	Generic name	Prior authorization
J1412	Roctavian	valoctocogene roxaparvovec-rvox	2/1/2026
J1449	Rolvedon	Hematopoietic - Eflapegrastim	4/1/2024
Q5119	Ruxience	Rituximab-pvvr	3/1/2024
J9333	Rystiggo	rozanolixizumab-noli	2/1/2026
Q9998	Selarsdi	ustekinumab-aekn	2/1/2026
J2327	Skyrizi IV	risankizumab-rzaa	3/1/2024
J3387	Skysona	elivaldogene autotemcel	2/1/2026
J1602	Simponi Aria®	golimumab	12/1/2020
J1299	Soliris®	eculizumab	12/1/2020
J2326	Spinraza®	nusinersen	12/1/2020
J3357	Stelara SQ	ustekinumab	3/1/2024
J3358	Stelara®	ustekinumab	12/1/2020
Q5099	Steqeyma	ustekinumab-stba	2/1/2026
Q5127	Stimufend	Pegfilgrastim-fpgk	4/1/2024
Q5157	Stoboclo	denosumab-bmwo	2/1/2026
J7321	Supartz	Hyaluronic Acid Derivatives	2/1/2026
J7331	Synjoynt	Hyaluronic Acid Derivatives	2/1/2026
J7325	Synvisc/ Synvisc-One	Hyaluronic Acid Derivatives	2/1/2026
Q2053	Tecartus	brexucabtagene autoleucel	2/1/2026
Q2057	Tecelra	afamitresgene autoleucel	2/1/2026
J3490, J3590, C9399	Tegsedi	inotersen	3/1/2024
J3241	Tepezza	teprotumumab-trbw	2/1/2026
Q5116	Trazimera	Trastuzumab-dttb	4/1/2024
J7332	Triluron	Hyaluronic Acid Derivatives	2/1/2026



A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

# Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®  
non-Medicare members

Revised April 1, 2026

HCPCS code	Brand name	Generic name	Prior authorization
J7329	Trivisc	Hyaluronic Acid Derivatives	2/1/2026
Q5115	Truxima	rituxamab -abbs	3/1/2024
Q5134	Tyruko	natalizumab-sztn	2/1/2026
J2323	Tysabri®	natalizumab	12/1/2020
Q5111	Udenyca	Pegfilgrastim-cbqv	4/1/2024
Q5111	Udenyca Onbody	Pegfilgrastim-cbqv	4/1/2024
J1303	Ultomiris®	ravulizumab-cwvz	12/1/2020
J2777	Vabysmo	faricimab-svoa	3/1/2024
Q5129	Vegzelma	Bevacizumab-adcd	4/1/2024
J7321	Visco-3	Hyaluronic Acid Derivatives	2/1/2026
J3401	Vyjuvek	beremagene geperpavec-svdt	2/1/2026
J9332	Vyvgart	Efgartigimod alfa-fcab	3/1/2024
J9334	Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	3/1/2024
Q5137	Wezlana	ustekinumab-auub	2/1/2026
Q5136	Wyost	denosumab-bbdz	2/1/2026
Q5159	Xbryk	denosumab-dssb	2/1/2026
J1558	Xembify®	immune globulin, human-klhw	12/1/2020
J0897	Xgeva®	denosumab	12/1/2020
Q5155	Yesafili	aflibercept-jbvf	2/1/2026
Q2041	Yescarta®	axicabtagene ciloleucel	12/1/2020
Q5100	Yesintek	ustekinumab-kfce	2/1/2026
Q5101	Zarxio	Filgrastim-sndz	4/1/2024
J3389	Zevaskyn	prademagene zamikeracel	2/1/2026
Q5120	Ziextenzo	Pegfilgrastim-bmez	4/1/2024
J3490	Zilbrysq	zilucoplan	2/1/2026
Q5118	Zirabev	Bevacizumab-bvzr	4/1/2024



A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

# Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®  
non-Medicare members

Revised April 1, 2026

HCPCS code	Brand name	Generic name	Prior authorization
J3399	Zolgensma®	onasemnogene abeparvovec-xioi	12/1/2020
J1748	Zymfentra SQ	infliximab-dyyb	2/1/2026
J3393	Zynteglo	betibeglogene autotemcel	2/1/2026